1217741-83-7
1217741-83-7
Chemical Structure
(±)-cis-Sertraline-d3 hydrochloride
- CAS No.: 1217741-83-7
- Formula:C17H15D3Cl3N
- Molecular Weight:345.71
IUPAC Name: (1S,4S)-4-(3,4-dichlorophenyl)-N-(methyl-d3)-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride
InChIKey: BLFQGGGGFNSJKA-FEGLBNOFSA-N
SMILES: [2H]C([2H])([2H])N[C@@H]1C2=CC=CC=C2[C@H](C3=CC(Cl)=C(C=C3)Cl)CC1.Cl
Biological Activity: (±)-cis-Sertraline-d3 (hydrochloride) is the deuterium labeled Sertraline hydrochloride. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(±)-cis-Sertraline-d3 hydrochloride | 99.54% | (±)-cis-Sertraline-d3 (hydrochloride) is the deuterium labeled Sertraline hydrochloride. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sertraline hydrochloride (Standard) | 99.95% | Sertraline (hydrochloride) (Standard) is the analytical standard of Sertraline (hydrochloride). This product is intended for research and analytical applications. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sertraline hydrochloride | 99.96% | Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Murdoch D, et al. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs. 1992 Oct;44(4):604-24. [Content Brief]
